Bone Biologics (BBLG) Return on Equity (2012 - 2025)

Bone Biologics (BBLG) has 14 years of Return on Equity data on file, last reported at 0.01% in Q4 2025.

• Return on Equity for Q4 2025 came in at 0.01%, up 1.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.01% (up 1.0% YoY), and the FY2025 annual result was 0.01%, up 1.0% from the prior year.
• Return on Equity improved to 0.01% in Q4 2025 per BBLG's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.0% in Q4 2021 and troughed at 0.03% in Q4 2023.
• A 5-year average of 0.01% and a median of 0.01% in 2022 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2023 and 2024: Return on Equity declined 2 bps in 2023, then rose 2 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2021, then plunged by 287 bps to 0.01% in 2022, then plunged by 301 bps to 0.03% in 2023, then jumped by 59 bps to 0.01% in 2024, then surged by 52 bps to 0.01% in 2025.
• Business Quant data shows BBLG's Return on Equity at 0.01% in Q4 2025, 0.01% in Q3 2025, and 0.01% in Q2 2025.